Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cytochrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    86 result(s) found for: Cytochrome. Displaying page 4 of 5.
    « Previous 1  2  3  4  5  Next»
    EudraCT Number: 2014-005350-19 Sponsor Protocol Number: TTD-14-05 Start Date*: 2015-06-26
    Sponsor Name:Grupo de Tratamiento de los Tumores Digestivos (TTD)
    Full Title: A phase I/II study of nab-paclitaxel (Abraxane®) and gemcitabine followed by modified FOLFOX (AG-mFOLFOX) in patients with previously untreated, metastatic pancreatic adenocarcinoma
    Medical condition: Metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-001752-42 Sponsor Protocol Number: PRESTO Start Date*: 2023-04-13
    Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH
    Full Title: The PRESTO Trial- Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1 and cT2N0, esophageal adenocarcinoma with indi...
    Medical condition: T1-T2N0 esophageal adenocarcinoma including gastroesophageal junction (GEJ) with indication for radical surgery
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003232-24 Sponsor Protocol Number: AVA-PED-301 Start Date*: 2020-12-03
    Sponsor Name:Dova Pharmaceuticals, Inc.
    Full Title: A Phase 3b, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment...
    Medical condition: Thrombocytopenia in paediatric subjects with immune thrombocytopenia for ≥6 months duration who have had an insufficient response to a previous treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043555 Thrombocytopenias HLT
    23.0 10005329 - Blood and lymphatic system disorders 10083843 Primary immune thrombocytopenia LLT
    23.0 10005329 - Blood and lymphatic system disorders 10083842 Immune thrombocytopenia PT
    20.0 10005329 - Blood and lymphatic system disorders 10035534 Platelet disorders HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000592-24 Sponsor Protocol Number: MR308-3501 Start Date*: 2017-03-15
    Sponsor Name:Mundipharma Research GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Multicenter, Placebo- and active Comparator-Controlled Study to evaluate Efficacy and Safety of MR308 in the Treatment of Acute Pain After Third Molar Tooth Extraction (...
    Medical condition: Acute pain after third molar tooth extraction; dental procedure must have involved extraction of at least two impacted third molars requireing bone removal. If only two impacted third molars are ex...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000023314 10066714 Acute pain LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002217-31 Sponsor Protocol Number: 2215-CL-0101 Start Date*: 2015-07-09
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
    Medical condition: Relapsed or Refractory Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000474-38 Sponsor Protocol Number: ZX008-1504 Start Date*: 2016-09-13
    Sponsor Name:Zogenix International Limited
    Full Title: A Multicenter, 2-Cohort Trial to First Assess the Pharmacokinetic and Safety Profile of a Single Dose of ZX008 (Fenfluramine Hydrochloride) Oral Solution When Added to Standard of Care (Cohort 1), ...
    Medical condition: Dravet's syndrome
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10073682 Dravet syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-000593-38 Sponsor Protocol Number: MR308-3502 Start Date*: 2016-12-05
    Sponsor Name:Mundipharma Research GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Multicenter, Placebo- and active Comparator-Controlled Study to evaluate Efficacy and Safety of MR308 in the Treatment of Acute Pain After Abdominal Hysterectomy Surgery...
    Medical condition: Acute pain after open total or subtotal abdominal hysterectomy
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004867 10066714 Acute pain LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed) SK (Completed) LV (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-007081-38 Sponsor Protocol Number: M10-300 Start Date*: 2009-10-08
    Sponsor Name:Abbott GmbH & Co KG
    Full Title: An Open-Label, Randomized Phase 2 Study of ABT-869 in Combination With mFOLFOX6 (Oxaliplatin, 5-Fluorouracil, and Folinic Acid) Versus Bevacizumab in Combination With mFOLFOX6 as Second-line Treatm...
    Medical condition: Advanced colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061451 Colorectal cancer PT
    9.1 10052358 Colorectal cancer metastatic LLT
    9.1 10052362 Metastatic colorectal cancer LLT
    9.1 10010030 Colorectal cancer recurrent LLT
    9.1 10010035 Colorectal cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PT (Completed) BE (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-004000-19 Sponsor Protocol Number: PAC326 Start Date*: 2014-05-12
    Sponsor Name:CTI BioPharma Corp.
    Full Title: A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Ess...
    Medical condition: Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) GB (Completed) DE (Temporarily Halted) HU (Prematurely Ended) CZ (Prematurely Ended) NL (Temporarily Halted) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-005223-28 Sponsor Protocol Number: GZGD02607 Start Date*: 2009-11-04
    Sponsor Name:Genzyme Europe B.V.
    Full Title: A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 who have Reached ...
    Medical condition: Gaucher Disease type I
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018048 Gaucher's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) FR (Completed) DE (Completed) ES (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021995-27 Sponsor Protocol Number: OXN3506 Start Date*: 2011-07-13
    Sponsor Name:Mundipharma Research GmbH & Co. KG
    Full Title: A randomised, double-blind, double-dummy, parallel-group multicenter study to demonstrate improvement in symptoms of constipation and non-inferiority in analgesic efficacy in subjects with non-mali...
    Medical condition: The intended indication is: Severe pain, which can be adequately managed only with opioid analgesics. The opioid antagonist naloxone is added to counteract opioid-induced constipation by blocki...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058019 Cancer pain PT
    16.1 10018065 - General disorders and administration site conditions 10033371 Pain PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) DE (Completed) FI (Completed) DK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2018-003107-19 Sponsor Protocol Number: CHDM201A2101 Start Date*: 2019-03-13
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase I/II multi-center study of HDM201 added to chemotherapy in adult subjects with relapsed/refractory (R/R) or newly diagnosed acute myeloid leukemia (AML)
    Medical condition: Relapsed refractory (R/R) or newly diagnosed acute myeloid leukemia (AML)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-009894-88 Sponsor Protocol Number: NCT-2008-11-01-1015 Start Date*: 2009-09-17
    Sponsor Name:University Hospital of Heidelberg
    Full Title: Lapatinib versus Lapatinib with Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A randomized phase II trial
    Medical condition: Gastric Cancer, cancer of the oesophago-gastric junction, esophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017758 Gastric cancer LLT
    9.1 10015362 Esophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-018118-21 Sponsor Protocol Number: OXN2503 Start Date*: Information not available in EudraCT
    Sponsor Name:Mundipharma Research GmbH & Co. KG
    Full Title: An exploratory, randomised, double-blind, placebo-controlled, parallel group, pilot study to assess the analgesic efficacy of oxycodone/naloxone prolonged release tablets (OXN PR) compared to place...
    Medical condition: Bladder Pain Syndrome (BPS), formerly addressed as IC/PBS (interstitial cystitis /Painful Bladder Syndrome)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10008927 Chronic interstitial cystitis LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-003506-11 Sponsor Protocol Number: IFCT-1703 Start Date*: 2019-01-23
    Sponsor Name:IFCT
    Full Title: Phase II trial of trastuzumab in combination with pertuzumab in pretreated patients with non-small cell lung cancer (NSCLC) harboring a Her2 mutation and receiving docetaxel
    Medical condition: Non small cell lung cancer with a Her2 mutation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    23.0 10010331 - Congenital, familial and genetic disorders 10075653 HER2 gene amplification PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-005222-37 Sponsor Protocol Number: GZGD02507 Start Date*: 2009-11-04
    Sponsor Name:Genzyme Europe B.V.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Confirming the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1
    Medical condition: Gaucher Disease type I
    Disease: Version SOC Term Classification Code Term Level
    13.1 10010331 - Congenital, familial and genetic disorders 10018048 Gaucher's disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-004610-35 Sponsor Protocol Number: AL-2001 Start Date*: 2021-03-16
    Sponsor Name:Allarity Therapeutics Europe Aps
    Full Title: Phase II, open label, single arm study to investigate anti-tumor effect of ixabepilone in patients with locally recurrent metastatic breast cancer (mBC) selected by the ixabepilone Drug Response Pr...
    Medical condition: Locally recurrent or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) PL (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-002901-31 Sponsor Protocol Number: OXN2504 Start Date*: 2011-11-25
    Sponsor Name:Mundipharma Research GmbH & Co. KG
    Full Title: A multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson's disease associated pain
    Medical condition: Subjects will have idiopathic Parkinson's disease and be suffering from severe PD associated pain.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2007-005933-12 Sponsor Protocol Number: E7080-G000-201 Start Date*: 2009-10-29
    Sponsor Name:Eisai Limited
    Full Title: Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified...
    Medical condition: Medullary thyroid cancer [MTC] or radioiodine (131*I) refractory/resistant differentiated thyroid cancer[DTC]: Determine the pharmacokinetic (PK) profile and the pharmacokinetic/pharmacodynamic (PK...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001491-35 Sponsor Protocol Number: CB103-C-101 Start Date*: 2017-08-11
    Sponsor Name:Cellestia Biotech AG
    Full Title: A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study with Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adu...
    Medical condition: advanced or metastatic solid tumours and haematological malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066476 Haematological malignancy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) NL (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 04:43:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA